An investigation of clinical and immunological events following repeated aerodigestive tract challenge infections with live Mycobacterium bovis Bacille Calmette Guérin

Author
Fernanda Schreiber, Zhiming Huo, Rafaela Giemza, Maria Woodrow, Nicola Fenner, Zoe Stephens, Gordon Dougan, Steven Prideaux, Luiz Castello-Branco, David Lewis
Abstract

Bacille Calmette Guérin substrain Moreau Rio de Janeiro is an attenuated strain of Mycobacterium bovis that has been used extensively as an oral tuberculosis vaccine. We assessed its potential as a challenge model to study clinical and immunological events following repeated mycobacterial gut infection. Seven individuals received three oral challenges with approximately 10(7) viable bacilli. Clinical symptoms, T-cell responses and gene expression patterns in peripheral blood were monitored. Clinical symptoms were relatively mild and declined following each oral challenge. Delayed T-cell responses were observed, and limited differential gene expression detected by microarrays. Oral challenge with BCG Moreau Rio de Janeiro vaccine was immunogenic in healthy volunteers, limiting its potential to explore clinical innate immune responses, but with low reactogenicity.

Year of Publication
2010
Journal
Vaccine
Volume
28
Issue
33
Number of Pages
5427-31
Date Published
07/2010
ISSN Number
1873-2518
DOI
10.1016/j.vaccine.2010.06.005
Alternate Journal
Vaccine
PMCID
PMC3764428
PMID
20558246
Download citation
Reactivity
Human
Category
T cell ELISPOT
Analyte
IFN-γ